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Malaria is among the most common preventable causes of adverse pregnancy 
outcomes. WHO recommends intermittent preventive treatment in pregnancy with 
sulfadoxine-pyrimethamine for HIV-negative women; however, parasite resistance now 
threatens the effectiveness of this approach. Over the past decade, researchers have 
investigated alternative strategies, including screen-and-treat approaches and drugs for 
intermittent use to replace sulfadoxine-pyrimethamine, but results were mostly 
disappointing.1 Apart from dihydroartemisinin-piperaquine,2,3 all other options— including 
low-dose mefloquine, amodiaquine, and a fixed dose-combination of chloroquine-
azithromycin1-4— were too poorly tolerated for intermittent treatment in pregnancy. It is 
unclear in the trial of chloroquine azithromycin whether poor tolerability resulted from the 
high dose of azithromycin (3 g per course), chloroquine, or their combination. A planned 
interim analysis showed no differences in suboptimum pregnancy outcomes relative to 
intermittent sulfadoxine-pyrimethamine, and the trial was terminated early on grounds of 
futility.4 As a result, the study was underpowered to test whether the degree of chloroquine 
resistance, which varied widely between the five participating countries, modified the 
effect. Thus, a key question remained unanswered: could chloroquine be reconsidered for 
preventive use in countries with high-grade sulfadoxine-pyrimethamine resistance and 
where chloroquine susceptibility had returned? 
 
Malawi was the first country in Africa to report renewed parasite sensitivity to 
chloroquine, about 8 years after withdrawing its use in 1993 in favour of sulfadoxine-
pyrimethamine.5 Chloroquine for antenatal chemoprevention, rather than 
dihydroartemisinin-piperaquine, would have the advantage of allowing the latter, an 
artemisinin-based combination therapy, to be reserved for first-line and second-line case 
management. Furthermore, chloroquine has well established dosing and safety profiles for 
treatment and chemoprophylaxis, including in the first trimester when sulfadoxine-
pyrimethamine is contraindicated but when malaria is an important risk factor for adverse 
pregnancy outcomes.6 
 
In The Lancet Infectious Diseases, Titus Divala and colleagues7 report the results of a 
three-arm randomised trial undertaken in 900 HIV-uninfected women in Malawi. 
Chloroquine monotherapy was given either as two-course intermittent preventive 
treatment or as weekly prophylaxis and compared with two-course intermittent 
sulfadoxine-pyrimethamine, which was the standard treatment at the time of the study. 
Despite well-documented high-grade sulfadoxine-pyrimethamine resistance in the study 
area, intermittent chloroquine was no better than sulfadoxine-pyrimethamine in preventing 
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placental malaria confirmed by histopathology (relative risk [RR] 1·00, 95% CI 0·67–1·50). 
When provided as weekly prophylaxis, the prevalence of placental malaria by 
histopathology was 25% lower in univariate analysis (RR 0·75, 95% CI 0·48–1·17; p=0·24), 
and 34% lower after adjusting for confounding (RR 0·66, 0·46–0·95; p=0·027). The risk of 
clinical malaria was also 78% lower with chloroquine prophylaxis compared with 
intermittent sulfadoxine-pyrimethamine (two vs nine cases; RR 0·22, 95% CI 0·05–0·90; 
p=0·063). This reduction in clinical malaria is similar to that seen in the two trials of 
intermittent preventive treatment in pregnancy with dihydroartemisinin-piperaquine, but 
the 25% reduction in placental malaria is much more modest than the 65% achieved with 
three courses of dihydroartemisinin-piperaquine.1-3 The absence of any difference between 
intermittent preventive treatment with sulfadoxine-pyrimethamine and intermittent 
chloroquine, and the relatively modest superior effect of weekly prophylaxis, is surprising, 
because a loading dose was given, each dose was supervised, and all infections at enrolment 
were chloroquine susceptible.  
 
Similar to previous studies with mefloquine, amodiaquine, and chloroquine-
azithromycin, intermittent chloroquine was poorly tolerated, with 94 (31%) of 300 women 
reporting at least one treatment-related adverse event, compared with four (1%) of 300 
assigned sulfadoxine-pyrimethamine. Dizziness (n=57) and vomiting (n=50) were reported 
most frequently. Low tolerance of the two-course intermittent regimen precludes assessing 
a strategy of more frequent monthly dosing with chloroquine. As prophylaxis, however, 
chloroquine was much better tolerated, consistent with findings of older trials,8 although 
the number reporting at least one adverse event was still higher than with intermittent 
sulfadoxine-pyrimethamine (RR 6·5, 95% CI 2·4–17·7; p<0·0001).  
 
Similar to trials with dihydroartemisinin-piperaquine and mefloquine, the reductions 
in placental malaria did not translate into fewer cases of low birthweight relative to 
intermittent sulfadoxine-pyrimethamine. One possible explanation is the potential 
protective effect of sulfadoxine-pyrimethamine against non-malarial causes of adverse 
pregnancy outcomes. Sulfadoxine-pyrimethamine has broad-spectrum antibacterial activity 
against Gram-positive bacteria.9 Furthermore, sulfadoxine is from the group of agents used 
to treat Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, and 
Gardnerella vaginalis, a bacterium associated commonly with bacterial vaginosis. Although 
sulfadoxine-pyrimethamine is unlikely to be curative of sexually transmitted infections or 
reproductive tract infections, it might reduce pathogen loads and maternal inflammatory 
responses.10  The performance of intermittent preventive treatment in pregnancy with 
sulfadoxine-pyrimethamine is noteworthy because chloroquine has well-known anti-
inflammatory properties, which could have improved pregnancy outcomes in the trial 
without altering non-malarial pathogen loads.  
 
Although there is a need for more effective malaria chemoprevention strategies in 
pregnancy in east and southern Africa, evidence from the trial by Divala and colleagues is 
unlikely to swing the pendulum back in favour of chloroquine prophylaxis. Nevertheless, 
with the return of chloroquine susceptibility in many parts of Africa, use of chloroquine in 
the first trimester might be worth investigating further. Future studies are needed to 
ascertain if intermittent preventive treatment in pregnancy with dihydroartemisinin-
piperaquine in the second and third trimesters is better than sulfadoxine-pyrimethamine at 
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reducing adverse pregnancy outcomes. If we can learn anything from this study and other 
trials, it is to temper our expectations. 
 
R Matthew Chico, *Feiko O ter Kuile 
London School of Hygiene & Tropical Medicine, London, UK (RMC); and Liverpool School of 
Tropical Medicine, Liverpool L3 5QA, UK (FOtK) feiko.terkuile@lstmed.ac.uk 
 
We declare no competing interests. 
 
References 
 
1. Desai M, Hill J, Fernandes S, et al. Prevention of malaria in pregnancy. Lancet Infect Dis. 
2018. 
2. Desai M, Gutman J, L'Lanziva A, et al. Intermittent screening and treatment or intermittent 
preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive 
treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in 
western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 
2015;386(10012):2507-2519. 
3. Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin-Piperaquine for the 
Prevention of Malaria in Pregnancy. N Engl J Med. 2016;374(10):928-939. 
4. Kimani J, Phiri K, Kamiza S, et al. Efficacy and safety of azithromycin-chloroquine versus 
sulfadoxine-pyrimethamine for intermittent preventive treatment of Plasmodium falciparum 
malaria infection in pregnant women in Africa: an open-label, randomized trial. PLOS ONE. 
2016;11(6):e0157045. 
5. Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in 
Malawi. N Engl J Med. 2006;355(19):1959-1966. 
6. Rogerson SJ, Desai M, Mayor A, Sicuri E, Taylor SM, van Eijk AM. Burden, pathology, and 
costs of malaria in pregnancy: new developments for an old problem. Lancet Infectious 
Diseases. 2018. 
7. Divala TH, Mungwira RG, Mawindo PM, et al. Chloroquine as chemoprophylaxis every week 
or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised 
controlled trial. Lancet Infect Dis. 2018;S1473-3099(18)30415-8.(http://dx.doi.org/10.1016/). 
8. Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria 
treatment and prevention in pregnancy: indications for use and adverse events associated 
with use of chloroquine or mefloquine. Am J Trop Med Hyg. 1996;55(1 Suppl):50-56. 
9. Capan M, Mombo-Ngoma G, Makristathis A, Ramharter M. Anti-bacterial activity of 
intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of 
sulphadoxine-pyrimethamine, mefloquine, and azithromycin. Malar J. 2010;9:303. 
10. Chico RM, Chaponda EB, Ariti C, Chandramohan D. Sulfadoxine-pyrimethamine exhibits 
dose-response protection against adverse birth outcomes related to malaria and sexually 
transmitted and reproductive tract infections. Clinical Infectious Diseases. 2017;64(8):1043-
1051. 
 
